BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Low D. The new oral cephalosporins in community-acquired infections. Clinical Microbiology and Infection 2000;6:64-9. [DOI: 10.1111/j.1469-0691.2000.tb02047.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Sader HS, Jones RN. Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. Expert Review of Anti-infective Therapy 2014;5:29-43. [DOI: 10.1586/14787210.5.1.29] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
2 Sader HS, Biedenbach DJ, Streit JM, Jones RN. Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections. International Journal of Antimicrobial Agents 2005;25:89-92. [DOI: 10.1016/j.ijantimicag.2004.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
3 Sader HS, Fritsche TR, Mutnick AH, Jones RN. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagnostic Microbiology and Infectious Disease 2003;47:515-25. [DOI: 10.1016/s0732-8893(03)00165-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
4 Jones RN, Sader HS. Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly? Diagnostic Microbiology and Infectious Disease 2006;55:351-6. [DOI: 10.1016/j.diagmicrobio.2006.04.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
5 Sader HS, Jacobs MR, Fritsche TR. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis 2007;57:5S-12S. [PMID: 17292577 DOI: 10.1016/j.diagmicrobio.2006.12.014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
6 Sader HS, Streit JM, Fritsche TR, Jones RN. Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: A sample of North American isolates. Diagnostic Microbiology and Infectious Disease 2004;49:283-7. [DOI: 10.1016/j.diagmicrobio.2004.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]